Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
IMMP 
Immutep Ltd ADR (IMMP)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: IMMP (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -72.33% | Avg. Invested days 21 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 264.45M USD | Price to earnings Ratio - | 1Y Target Price 9.5 |
Price to earnings Ratio - | 1Y Target Price 9.5 | ||
Volume (30-day avg) 70891 | Beta 1.98 | 52 Weeks Range 1.65 - 3.33 | Updated Date 03/31/2025 |
52 Weeks Range 1.65 - 3.33 | Updated Date 03/31/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.2 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -839.24% |
Management Effectiveness
Return on Assets (TTM) -20.35% | Return on Equity (TTM) -30.45% |
Valuation
Trailing PE - | Forward PE 7.65 | Enterprise Value 157045588 | Price to Sales(TTM) 52.81 |
Enterprise Value 157045588 | Price to Sales(TTM) 52.81 | ||
Enterprise Value to Revenue 803.42 | Enterprise Value to EBITDA -2.94 | Shares Outstanding 145559008 | Shares Floating 1251923482 |
Shares Outstanding 145559008 | Shares Floating 1251923482 | ||
Percent Insiders 0.01 | Percent Institutions 2.06 |
Analyst Ratings
Rating 4.5 | Target Price 9.5 | Buy 1 | Strong Buy 1 |
Buy 1 | Strong Buy 1 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Immutep Ltd ADR
Company Overview
History and Background
Immutep Ltd ADR (IMMP) is an Australian biotechnology company founded in 2001. It focuses on developing LAG-3 related immunotherapy products for the treatment of cancer and autoimmune diseases. A significant milestone was the clinical validation of LAG-3 as an immune checkpoint target.
Core Business Areas
- LAG-3 Immunotherapy: Development of therapeutic antibodies targeting the LAG-3 immune control point. This includes products in clinical trials for cancer treatment.
Leadership and Structure
The leadership team includes Frederic Triebel (CMO & CSO), Marc Voigt (CEO), and Deanne Miller (CFO). The organizational structure is typical of a biotechnology company, with research and development, clinical operations, and business development functions.
Top Products and Market Share
Key Offerings
- Eftilagimod Alpha (efti): A soluble LAG-3 protein designed to activate antigen presenting cells. Currently in clinical trials for various cancers, including non-small cell lung cancer (NSCLC), melanoma, and head and neck cancer. Market share is currently small as the product is not yet approved. Competitors in this area include pharmaceutical companies developing other checkpoint inhibitors such as Merck (Keytruda), Bristol Myers Squibb (Opdivo), and Roche (Tecentriq).
Market Dynamics
Industry Overview
The immunotherapy market is experiencing rapid growth, driven by the success of checkpoint inhibitors and other immunotherapeutic approaches. Competition is intense, with many companies developing novel therapies.
Positioning
Immutep is positioned as a leader in LAG-3 immunotherapy, a relatively new area of checkpoint inhibition. Its competitive advantage lies in its expertise in LAG-3 biology and its portfolio of LAG-3 targeting products.
Total Addressable Market (TAM)
The TAM for cancer immunotherapy is estimated to be over $100 billion annually. Immutep is positioned to capture a portion of this market through its LAG-3 targeting therapies.
Upturn SWOT Analysis
Strengths
- Pioneering LAG-3 immunotherapy
- Strong intellectual property portfolio
- Experienced management team
- Promising clinical trial results
Weaknesses
- Limited financial resources compared to larger pharmaceutical companies
- Dependence on clinical trial success
- No currently marketed products
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion of clinical trials into new indications
- Potential for regulatory approval of its lead product, Efti
- Increasing market demand for novel immunotherapies
Threats
- Competition from other immunotherapy approaches
- Clinical trial failures
- Regulatory hurdles
- Patent challenges
Competitors and Market Share
Key Competitors
- MRK
- BMY
- ROSY
Competitive Landscape
Immutep has a leadership position in LAG-3 immunotherapy, but it faces competition from larger pharmaceutical companies developing other immunotherapies. Its success depends on demonstrating superior efficacy and safety compared to existing treatments.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by advancements in its clinical programs and partnerships.
Future Projections: Future growth depends on the successful development and commercialization of its LAG-3 targeting therapies. Analyst estimates vary widely, reflecting the uncertainty of clinical trial outcomes.
Recent Initiatives: Recent initiatives include advancing clinical trials for efti in various cancer indications and seeking partnerships to expand its pipeline.
Summary
Immutep is a clinical-stage biotech company with a promising pipeline focused on LAG-3 immunotherapy. While it holds a strong position in this niche, it faces significant risks associated with clinical trials and competition from larger companies. Success hinges on demonstrating clinical efficacy and securing partnerships. Monitoring cash flow and clinical developments are critical for investors.
Similar Companies
- MRK
- BMY
- AZN
- ROSY
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- ClinicalTrials.gov
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. The information provided is based on publicly available data and is subject to change. Investing in biotechnology companies involves significant risks.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Immutep Ltd ADR
Exchange NASDAQ | Headquaters Sydney, NSW, Australia | ||
IPO Launch date 2012-04-17 | CEO, MD, CFO, Chief Business Officer & Executive Director Mr. Marc Voigt | ||
Sector Healthcare | Industry Biotechnology | Full time employees - | Website https://www.immutep.com |
Full time employees - | Website https://www.immutep.com | ||
Immutep Limited, a late-stage biotechnology company, engages in developing novel LAG-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alpha (efti or IMP321), a soluble LAG-3lg fusion based, which is in clinical development for the treatment of different types of cancers. The company's product pipeline also includes TACTI-004, which is in phase III clinical trial for the treatment of first line non-small cell lung cancer (1L NSCLC); TACTI-003, which is in phase IIb clinical trial to treat first line head and neck squamous cell carcinoma (HNSCC); TACTI-002, which in phase II trial for the treatment NSCLC and HNSCC; AIPAC-003, which is in phase II/III clinical trial to treat metatastic breast cancer; and EFTISARC-NEO, which is in phase II clinical trial for the treatment of soft tissue sarcoma. In addition, it develops INSIGHT-003, which is in phase I to treat 1L NSCLC and solid tumors; INSIGHT-005, which is in phase I to treat metastatic urothelial cancer; IMP761, which is in preclinical trial to treat autoimmune disease; and IMP731 and IMP701 which is in clinical development. Further, the company develops LAG525, which is in phase II clinical trial to treat solid tumors and blood cancer, triple negative breast cancer, and melanoma; and in phase I to treat triple negative breast cancer. Immutep has collaboration with Merck & Co., Inc., GlaxoSmithKline, EOC Pharma, Novartis, and Laboratory Corporation of America Holdings. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is based in Sydney, Australia.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.